Ronacaleret in osteoporosis

Nature Reviews Endocrinology

Volumn 8, Issue 2, 2012, Pages 67-

  Diaz, Rosanne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM SENSING RECEPTOR; PARATHYROID HORMONE[1-34]; PLACEBO; RONACALERET;

BONE DENSITY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; FRAGILITY FRACTURE; HEALTH CARE PERSONNEL; HIP FRACTURE; HUMAN; NOTE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SPINE FRACTURE; TRABECULAR BONE;

EID: 84856408491     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.212     Document Type: Note

References (1)

1. Fitzpatrick, A. et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J. Bone Miner. Res. doi:10.1002/jbmr.554